% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Guberina:156721,
author = {M. Guberina and A. Sak and C. Pöttgen and I.
Tinhofer-Keilholz$^*$ and V. Budach$^*$ and P. Balermpas and
J. Von der Grün$^*$ and C. M. Rödel$^*$ and E. Gikka and
A.-L. Grosu$^*$ and A. Abdollahi$^*$ and J. Debus$^*$ and C.
Belka$^*$ and S. Pigorsch$^*$ and S. Combs$^*$ and D.
Mönnich$^*$ and D. Zips$^*$ and C. De-Colle and S. Welz and
A. Linge$^*$ and F. Lohaus$^*$ and G. Baretton$^*$ and T.
Gauler and M. Baumann$^*$ and M. Krause$^*$ and M.
Schuler$^*$ and A. Bankfalvi and B. Höing and S. Lang and
M. Stuschke},
title = {{ERCC}2 gene single-nucleotide polymorphism as a prognostic
factor for locally advanced head and neck carcinomas after
definitive cisplatin-based radiochemotherapy.},
journal = {The pharmacogenomics journal},
volume = {21},
number = {1},
issn = {1473-1150},
address = {Basingstoke},
publisher = {Nature Publishing Group},
reportid = {DKFZ-2020-01059},
pages = {37-46},
year = {2021},
note = {2021 Feb;21(1):37-46},
abstract = {Identifying patients with locally advanced head and neck
carcinoma on high risk of recurrence after definitive
concurrent radiochemotherapy is of key importance for the
selection for consolidation therapy and for individualized
treatment intensification. In this multicenter study we
analyzed recurrence-associated single-nucleotide
polymorphisms (SNPs) in DNA repair genes in tumor DNA from
132 patients with locally advanced head and neck carcinoma
(LadHnSCC). Patients were treated with definitive
radiotherapy and simultaneous cisplatin-based chemotherapy
at six partner sites of the German Cancer Consortium (DKTK)
Radiation Oncology Group from 2005 to 2011. For validation,
a group of 20 patients was available. Score selection method
using proportional hazard analysis and leave-one-out
cross-validation were performed to identify markers
associated with outcome. The SNPs rs1799793 and rs13181 were
associated with survival and the same SNPs and in addition
rs17655 with freedom from loco-regional relapse (ffLRR) in
the trainings datasets from all patients. The homozygote
major rs1799793 genotype at the ERCC2 gene was associated
with better (Hazard ratio (HR): 0.418 (0.234-0.744),
p = 0.003) and the homozygote minor rs13181 genotype at
ERCC2 with worse survival (HR: 2.074, $95\%$ CI
(1.177-3.658), p = 0.017) in comparison to the other
genotypes. At the ffLRR endpoint, rs1799793 and rs13181 had
comparable prognostic value. The rs1799793 and rs13181
genotypes passed the leave-one-out cross-validation
procedure and associated with survival and ffLRR in patients
with LadHnSCC treated with definitive radiochemotherapy.
While findings were confirmed in a small validation dataset,
further validation is underway within a prospective
biomarker study of the DKTK.},
cin = {BE01 / FR01 / HD01 / FM01 / E210 / E050 / M010 / DD01 /
MU01 / TU01 / ED01},
ddc = {610},
cid = {I:(DE-He78)BE01-20160331 / I:(DE-He78)FR01-20160331 /
I:(DE-He78)HD01-20160331 / I:(DE-He78)FM01-20160331 /
I:(DE-He78)E210-20160331 / I:(DE-He78)E050-20160331 /
I:(DE-He78)M010-20160331 / I:(DE-He78)DD01-20160331 /
I:(DE-He78)MU01-20160331 / I:(DE-He78)TU01-20160331 /
I:(DE-He78)ED01-20160331},
pnm = {315 - Bildgebung und Radioonkologie (POF4-315)},
pid = {G:(DE-HGF)POF4-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:32546699},
doi = {10.1038/s41397-020-0174-1},
url = {https://inrepo02.dkfz.de/record/156721},
}